A & T Respiratory Medicine

  Background  The mortality rate of community-acquired pneumonia (CAP) is high in adult patients. The highest mortality has been registered in patients in the older age group with a steady rise in the incidence of morbidity in younger people of working age.  There is a need to focus research on the role of neutrophils in the pathogenesis of pneumonia as CAP largely determines the outcomes of the same. This research is aimed at evaluating the indices of neutrophils oxidized-modified proteins and oxidative stress in patients with CAP, depending on the severity, and comparison of the frequency of neutrophil extracellular traps responsible for causing the progress of pneumonia.  Introduction The development of CAP is diverse among different patients. It is dependent on the etiology and the pathways of penetration of the microorganisms into the lungs.  The evaluation of the changes in the metabolic and functional status of neutrophils could be one of the urgent areas of research, as their

  Objective The soluble form of guanylate cyclase (sGC) stimulator riociguat has been approved for the management of patients with PAH (pulmonary arterial hypertension). It is also approved for the treatment of inoperable or recurrent/persistent chronic thromboembolic pulmonary hypertension after its safety and efficacy were assessed during the phase 3 randomized trials.  This EXPERT (EXPosurE Registry RiociguaT) study in patients with pulmonary hypertension is designed to assess the long-term safety of this medication in clinical practice. Methods EXPERT is an international, non-interventional prospective, multicenter, uncontrolled, cohort study of patients who were administered riociguat. During this study, patients were followed up for at least one year and up to four years from the enrollment or for 30 days after they stopped riociguat treatment.  The safety outcomes were related to the serious adverse events (SAEs) and adverse events (AEs) coded using Medical Dictionary for the Sy

  CLICK HERE TO JOIN It is common for physicians and nurses to face ethical dilemmas every day while providing care to patients, especially those with critical illnesses. The situations where the answer can be “right” are very rare in such cases.  This is especially more common during EOL (end-of-life) care, where the patient and caregivers might experience extreme emotions like grief, sadness, and loss. Oncologists often have to act as mediators through such difficult moments by advocating for their patients and connecting their caregivers with resources that would help them during the challenging phase. During EOL care, the ethical dilemma may arise due to situations like patient's independence being compromised, communication breakdowns, lack of effective symptom management, shared decision making, and non-beneficial care.  Physicians often have to navigate through such ethical dilemmas by suggesting the best possible treatment and advice while allowing patients and their family

  CLICK HERE TO JOIN ME Lung and airway infections are commonly referred to as pulmonary or respiratory infections. Chronic bronchitis, COPD, influenza, tuberculosis, and pneumonia are some of the major forms of respiratory infections.  Nasopharyngeal infections that result in nasal discharge, bronchitis that leads to cough and sputum, and pneumonia that leads to cough with sputum can also increase the respiratory rate and lead to breathing difficulties.  There are several viruses that contribute to the increased incidence of bronchitis, while bacteria are known to contribute to pneumonia.  These infections usually spread from infected patients to healthy people through contaminated droplets released into the air when the infected person sneezes and coughs. These respiratory conditions are the leading causes of mortality and morbidity from infectious diseases across the world. Nearly four million people are estimated to die due to acute respiratory infection every year. About 98% of th

  Over the last few months, researchers have been working tirelessly to find out everything possible about SARS-CoV-2. And some of the facts they have learned are quite alarming.  Doctors no longer believe that once a person tests COVID negative after being treated for this infection, he is safe.  Research studies and clinical experience have shown that COVID-19 can create havoc in your body even after it has been treated or after you have recovered from the initial bout of illness. The infection tends to produce longer-lasting effects that may worsen or show up with variable intensity in the future.  Our ‘COVID19 PANDEMIC BY EXPERTS IN THE FIELD WEBINAR’ is focused on providing information about the latest developments in COVID-19 including the short-term and long-term complications this infection can cause. You can join this webinar to stay updated about the different ways COVID-19 can create havoc in the patient’s body.  While COVID-19 is widely known to affect the lungs, there is

  What Is The Role O f Nicotine Addiction In COPD Management ?   COPD is a chronic progressive disorder that is characterized by breathing difficulties that tend to become worse over a period of time. Initially, patients may experience occasional episodes of dyspnea. However,as the disease progresses, the episodes tend to occur more frequently. Also, it can make it increasingly difficult for patients to perform physical activities. In advanced cases, patients may experience dyspnea after walking a few steps or even at rest. The progress of these symptoms can be slowed down by identifying and eliminating the risk factors for COPD. Cigarette smoking is the most common contributor to the development of COPD and asthma. It can not just trigger the development of these diseases but also accelerate their progress thereby increasing the risk of morbidity and mortality significantly. Hence, the treatment of COPD must be focused on nicotine de-addiction. It should be noted that th